Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer.

Park HJ, Park JB, Lee SJ, Song M.

Int J Mol Sci. 2017 Aug 11;18(8). pii: E1746. doi: 10.3390/ijms18081746.

2.

Oral squamous cell cancer protein-protein interaction network interpretation in comparison to esophageal adenocarcinoma.

Khayer N, Zamanian-Azodi M, Mansouri V, Ghassemi-Broumand M, Rezaei-Tavirani M, Heidari MH, Rezaei Tavirani M.

Gastroenterol Hepatol Bed Bench. 2017 Spring;10(2):118-124.

3.

Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations.

Friedman AA, Xia Y, Trippa L, Le LP, Igras V, Frederick DT, Wargo JA, Tanabe KK, Lawrence DP, Neuberg DS, Flaherty KT, Fisher DE.

Clin Cancer Res. 2017 Aug 15;23(16):4680-4692. doi: 10.1158/1078-0432.CCR-16-3029. Epub 2017 Apr 26.

PMID:
28446504
4.

The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer.

Wu DW, Lin PL, Wang L, Huang CC, Lee H.

Theranostics. 2017 Feb 27;7(5):1114-1132. doi: 10.7150/thno.18175. eCollection 2017.

5.

Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.

Kim SJ, Kim JH, Yang B, Jeong JS, Lee SW.

Mol Ther. 2017 Feb 1;25(2):356-367. doi: 10.1016/j.ymthe.2016.11.005.

PMID:
28153088
6.

Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation.

Huang CJ, Huang SH, Chien CC, Lee HH, Yang SH, Chang CC, Lee CL.

Oncol Lett. 2016 Dec;12(6):4427-4434. doi: 10.3892/ol.2016.5275. Epub 2016 Oct 18.

7.

Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer.

Zhong L, Yang J, Cao Z, Chen X, Hu Y, Li L, Yang S.

Oncotarget. 2017 Feb 21;8(8):12843-12854. doi: 10.18632/oncotarget.14597.

8.

Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.

Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran PJ, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ, Wheeler DL.

Mol Cancer Ther. 2016 Sep;15(9):2175-86. doi: 10.1158/1535-7163.MCT-16-0012. Epub 2016 Jul 15.

9.

Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.

Perez M, Lucena-Cacace A, Marín-Gómez LM, Padillo-Ruiz J, Robles-Frias MJ, Saez C, Garcia-Carbonero R, Carnero A.

Oncotarget. 2016 May 31;7(22):33111-24. doi: 10.18632/oncotarget.8880. Erratum in: Oncotarget. 2016 Nov 22;7(47):78219.

11.
12.

Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays.

Lee JA, Shinn P, Jaken S, Oliver S, Willard FS, Heidler S, Peery RB, Oler J, Chu S, Southall N, Dexheimer TS, Smallwood J, Huang R, Guha R, Jadhav A, Cox K, Austin CP, Simeonov A, Sittampalam GS, Husain S, Franklin N, Wild DJ, Yang JJ, Sutherland JJ, Thomas CJ.

PLoS One. 2015 Jul 15;10(7):e0130796. doi: 10.1371/journal.pone.0130796. eCollection 2015.

13.

Targeting KRAS Oncogene in Colon Cancer Cells with 7-Carboxylate Indolo[3,2-b]quinoline Tri-Alkylamine Derivatives.

Brito H, Martins AC, Lavrado J, Mendes E, Francisco AP, Santos SA, Ohnmacht SA, Kim NS, Rodrigues CM, Moreira R, Neidle S, Borralho PM, Paulo A.

PLoS One. 2015 May 29;10(5):e0126891. doi: 10.1371/journal.pone.0126891. eCollection 2015.

14.

Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.

Tsukihara H, Nakagawa F, Sakamoto K, Ishida K, Tanaka N, Okabe H, Uchida J, Matsuo K, Takechi T.

Oncol Rep. 2015 May;33(5):2135-42. doi: 10.3892/or.2015.3876. Epub 2015 Mar 23.

15.

Systems approach for the selection of micro-RNAs as therapeutic biomarkers of anti-EGFR monoclonal antibody treatment in colorectal cancer.

Deyati A, Bagewadi S, Senger P, Hofmann-Apitius M, Novac N.

Sci Rep. 2015 Jan 27;5:8013. doi: 10.1038/srep08013.

16.

The efficacy of cetuximab in a tissue-engineered three-dimensional in vitro model of colorectal cancer.

Magdeldin T, López-Dávila V, Villemant C, Cameron G, Drake R, Cheema U, Loizidou M.

J Tissue Eng. 2014 Jul 17;5:2041731414544183. doi: 10.1177/2041731414544183. eCollection 2014.

17.

Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours.

Baro M, de Llobet LI, Figueras A, Skvortsova I, Mesia R, Balart J.

Br J Cancer. 2014 Sep 23;111(7):1310-8. doi: 10.1038/bjc.2014.432. Epub 2014 Jul 31.

18.

Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy.

Musiani D, Konda JD, Pavan S, Torchiaro E, Sassi F, Noghero A, Erriquez J, Perera T, Olivero M, Di Renzo MF.

FASEB J. 2014 Sep;28(9):4055-67. doi: 10.1096/fj.13-247924. Epub 2014 Jun 5.

19.

Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.

Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani B, Parsons SJ, De Placido S, Bianco R.

Breast Cancer Res. 2014 May 5;16(3):R45. doi: 10.1186/bcr3650.

20.

Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies.

Leto SM, Trusolino L.

J Mol Med (Berl). 2014 Jul;92(7):709-22. doi: 10.1007/s00109-014-1161-2. Epub 2014 May 10. Review.

Supplemental Content

Support Center